Pegasus Biotech Incorporated: federal grants and contributions: 11 agreements; $2.0M value; 3 departments; 6 programs.
Assay record ASY-CA-0E92L711X6 · Cite as: Assay Systems, “Pegasus Biotech Incorporated: federal grants and contributions”, https://assay-systems.com/register/ca/grants/r/pegasus-biotech-incorporated/
CIIP Singapore -PEGASUS-BPE-CAR-T: Cell and gene therapy manufacturing faces major bottlenecks due to low-yield, high-cost, and difficult-to-scale plasmid DNA systems that limit efficient viral production. Pegasus Bio and CellVec are partnering to commercialize a high-performance plasmid DNA vector platform optimized for CAR-T and CAR-NK manufacturing. The project delivers a cost-effective, scalable, and regulatory-ready solution for gene delivery, improving expression, safety, and production efficiency. The PB BPE plasmid system will be offered to CGT developers through licensing and CDMO par
This project leverages the combined vaccine development platform technologies of Pegasus Biotech, ConserV Bio and 4BaseBio to evaluate and enhance the manufacturing capability of a novel Canadian plasmid DNA technology platform (BPE) in the production of a new class of human influenza vaccines based on ConserV Bio's FLU-v technology.
The BPE technology is a novel, DNA plasmid backbone/production method that is ultra-low-cost, and has superior transfection efficiency. The technology has been demonstrated at lab scale (1.0 L fermentation), and needs to be scaled up to a commercially viable pilot scale to aid commercialization, and support projects to market the technology. This project ultimately scales up the process to 20-30 L fermentation along with associated downstream processes.
Pegasus Biotech is developing the process and analytical methods to commercialize the BPE plasmid technology as a DNA plasmid production platform.
Hire specialized expertise for DNA vaccine platform development
Hire expertise in international business development
This International Co-Innovation Action Program (ICAP) project will prepare the Firm to enter into future international co-innovation work.
Pegasus Biotech is developing a DNA vaccine development platform to provide accelerated vaccine development services to new and existing clients.
The Project will support development of intellectual property capacity within the Firm.
Participation in the Canadian medical biotechnology co-innovation mission to the Eureka Global Innovation Summit and Swiss Biotech Day in Switzerland – May 3 to 8, 2026. Delegation led by the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to develop international partnerships and potential project ideas under the Eureka Programs.
The purpose of the Canadian International Innovation Program (CIIP) contribution agreement is to support Canadian SMEs identify international partners in CIIP target countries for industrial research and development collaboration that has good potential for commercialization.
Contains information licensed under the Open Government Licence – Canada. Source: Government of Canada proactive disclosure of grants and contributions (open.canada.ca, dataset 432527ab-7aac-45b5-81d6-7597107a7013), 1,327,352 rows as published, collapsed to one agreement per agreement number (per reference number where none is given) at its latest amendment, which carries the full agreement value. Years are the agreement start year. Agreements with individuals are counted but not named.